Survodutide
Also known as: BI 456906, BI-456906
Classification
Peptide
Regulatory Status
n/a
Sources
4
Review
n/a
Overview
Survodutide (BI 456906) is an investigational dual agonist of the glucagon receptor and GLP-1 receptor studied for obesity and MASH with fibrosis.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
incretin-signalingenergy-expenditurehepatic-lipid-metabolismglucagon receptor agonismGLP-1 receptor agonismGCGRGLP-1R
Interactions & cautions
Drug interactions
other GLP-1 or dual/triple incretin agonists — Additive GI and metabolic effects may occur. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw